[HTML][HTML] Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
…, B Kaufman, T Yamashita, YS Lu, K Inoue… - … England Journal of …, 2019 - Mass Medical Soc
Background PIK3CA mutations occur in approximately 40% of patients with hormone receptor
(HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer. …
(HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer. …
MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy
…, M Toi, P Neven, J Sohn, K Inoue… - Journal of clinical …, 2017 - ascopubs.org
Purpose MONARCH 2 ( ClinicalTrials.gov identifier: NCT02107703) compared the efficacy
and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus …
and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus …
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double …
…, H Yoshizawa, Y Yanagita, H Sakai, K Inoue… - The lancet …, 2009 - thelancet.com
Background Palonosetron is a second-generation 5-hydroxytryptamine 3 (5-HT 3 )-receptor
antagonist that has shown better efficacy than ondansetron and dolasetron in preventing …
antagonist that has shown better efficacy than ondansetron and dolasetron in preventing …
Feature-based correlation and topological similarity for interbeat interval estimation using ultrawideband radar
…, H Taki, T Sato, M Yoshioka, K Inoue… - IEEE Transactions …, 2015 - ieeexplore.ieee.org
The objectives of this paper are to propose a method that can accurately estimate the
human heart rate (HR) using an ultrawideband (UWB) radar system, and to determine the …
human heart rate (HR) using an ultrawideband (UWB) radar system, and to determine the …
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer …
…, R Enrico, A Tomoyuki, F Takaaki, I Kenichi… - The Lancet, 2020 - thelancet.com
Background Pembrolizumab monotherapy showed durable antitumour activity and manageable
safety in patients with metastatic triple-negative breast cancer. We aimed to examine …
safety in patients with metastatic triple-negative breast cancer. We aimed to examine …
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo …
…, J Horiguchi, JH Muguiro, S Iacobelli, K Inoue… - The Lancet …, 2020 - thelancet.com
Background CLEOPATRA was a phase 3 study comparing the efficacy and safety of pertuzumab,
trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel in patients with …
trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel in patients with …
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled …
…, SB Kim, EH Jakobsen, A Ciceniene, K Inoue… - The lancet …, 2017 - thelancet.com
Background ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine
kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-…
kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-…
The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy …
GW Sledge, M Toi, P Neven, J Sohn, K Inoue… - JAMA …, 2020 - jamanetwork.com
Importance Statistically significant overall survival (OS) benefits of CDK4 and CDK6 inhibitors
in combination with fulvestrant for hormone receptor (HR)–positive, ERBB2 (formerly HER2…
in combination with fulvestrant for hormone receptor (HR)–positive, ERBB2 (formerly HER2…
Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with …
K Inoue, K Nakagami, M Mizutani, Y Hozumi… - Breast cancer research …, 2010 - Springer
We evaluated the efficacy and safety of sequential therapy with trastuzumab monotherapy (H-mono)
followed by H plus docetaxel (D) after disease progression (H → H + D) versus …
followed by H plus docetaxel (D) after disease progression (H → H + D) versus …
Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial
A Awada, R Colomer, K Inoue, I Bondarenko… - JAMA …, 2016 - jamanetwork.com
… Dr Inoue received research grants from Puma Biotechnology Inc and Pfizer in relation to
the study in question. Dr Inoue also received research grants from Novartis, GlaxoSmithKline, …
the study in question. Dr Inoue also received research grants from Novartis, GlaxoSmithKline, …
